
A new article was just published in Frontiers in Pharmacology: “Association between statin therapy and dementia risk: evidence from All of Us and UK Biobank with coenzyme Q7-related mediation analysis.”
I make this very simple. I am just copy-pasting the important parts of the paper with some minimal explanation.
Introduction:
“a population-based retrospective cohort study using the All of Us Research Program (discovery cohort, n = 83,355; 31,513 statin users) and UK Biobank (replication cohort, n = 173,282; 43,976 statin users). Participants were adults aged ≥40 years who self-identified as White, followed from 2006 through 2023 (discovery) and 2017 (replication). Inverse probability of treatment weighting balanced baseline characteristics. Dementia risk was estimated using Cox proportional hazards models. An exploratory mediation analysis examined low-density lipoprotein cholesterol (LDL-C) and coenzyme Q7, a protein involved in CoQ10 biosynthesis, as potential pathways linking statin use and dementia.”
Meaning:
They evaluated data for thousands of people for 17 years, looking at how many of them developed dementia among those taking statins and those not taking statins.
Results:
“Statin use was associated with significantly increased dementia risk in both cohorts (discovery: adjusted HR 2.22, 95% CI 2.02–2.44; replication: adjusted HR 2.54, 95% CI 1.98–3.33). Clear intensity-dependent relationships were observed, with high-intensity statins conferring 14% greater risk than moderate-to-low intensity therapy. In the exploratory mediation analysis, the estimated indirect effect through coenzyme Q7 was statistically significant and accounted for 8.2% of the total association, whereas the indirect effect through LDL-C was not statistically significant.”
Meaning:
Statins causing dementia had a hazard ratio (HR) of 2.22 and, with replication, an even larger HR of 2.54; both were significant (HR>=2), which warrants further evaluation to assess causation. However, when they looked at the association between LDL and dementia, there was no correlation.
Conclusion:
“Statin use was associated with higher dementia risk in both cohorts, and exploratory mediation findings suggested a modest statistical indirect association through COQ7, which should be considered hypothesis-generating. Given the observational design and conflicting evidence in the literature, these findings warrant further investigation before informing clinical decisions about statin therapy.”
Checked for CoQ7 levels (a marker for CoQ10):
(Coenzyme 7 was measurable in the blood because it is a good proxy for CoQ10. When people take statins, it blocks CoQ10 synthesis.)
“Higher COQ7 levels were significantly associated with lower odds of dementia (OR: 0.851, 95% CI: 0.744–0.973; P = 0.018), whereas LDL-C levels were not significantly associated with dementia (OR: 0.955, 95% CI: 0.832–1.095; P = 0.509). Restricted cubic spline analysis showed an overall association between COQ7 levels and dementia (P = 0.009), with evidence of nonlinearity (P = 0.044). Lower COQ7 levels were associated with higher odds of dementia relative to the median, with a flattening of the curve above the median. No significant overall association or nonlinearity was observed for LDL-C (P for overall association = 0.700; P for nonlinearity = 0.887)”.
Meaning:
Since statins reduce CoQ10, thereby CoQ7, they could show via blood that statin use increased dementia but having higher levels of CoQ7 (thereby 10), was beneficial. Here you need to look at the P value. Depending on what they set as their target level, they found P = 0.018 significant (usually P =< 0.05 is significant), and they found LDL-C not significant at P = 0.509; in another test for nonlinearity, they found an even weaker P = 0.887.
My summary:
- Don’t worry about higher LDL. It’s not harming you.
- Don’t take statins. Statins are harmful to your health.
There you have it.
Comments are welcome, as always, and are moderated for appropriateness.
Angela
